Tianjin Pharmaceutical da Ren Tang Group Ltd 2019 Annual Report
Company: Tianjin Pharmaceutical da Ren Tang Group Ltd
Sector: Manufacturing
Country: China
Year: 2019
Type: Annual Report
Pages: 232
The report describes a year of continued growth and operational strengthening for the company, with FY2019 Group revenue of approximately RMB6,994 million. It highlights RMB126 million invested in science and technology, equal to 5.82% of total investment, alongside continued research, product development, and quality-management efforts. The company also recruited 157 people and expanded training and talent-development activities. Its sustainability reporting section identifies energy, water, emissions, effluents and waste, occupational health and safety, diversity, and product responsibility as relevant topics.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.